CN105764517A - 用持续药物递送植入物治疗眼部病状的方法 - Google Patents

用持续药物递送植入物治疗眼部病状的方法 Download PDF

Info

Publication number
CN105764517A
CN105764517A CN201480062403.7A CN201480062403A CN105764517A CN 105764517 A CN105764517 A CN 105764517A CN 201480062403 A CN201480062403 A CN 201480062403A CN 105764517 A CN105764517 A CN 105764517A
Authority
CN
China
Prior art keywords
implant
plga
eye
bio
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480062403.7A
Other languages
English (en)
Chinese (zh)
Inventor
J-G·夏
R·布哈盖特
W·M·布兰达
T·尼维吉利
L·彭
D·周
D·A·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105764517(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN105764517A publication Critical patent/CN105764517A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CN201480062403.7A 2013-11-15 2014-11-14 用持续药物递送植入物治疗眼部病状的方法 Pending CN105764517A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
US61/904,887 2013-11-15
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Publications (1)

Publication Number Publication Date
CN105764517A true CN105764517A (zh) 2016-07-13

Family

ID=52001114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480062403.7A Pending CN105764517A (zh) 2013-11-15 2014-11-14 用持续药物递送植入物治疗眼部病状的方法

Country Status (24)

Country Link
US (2) US20150140062A1 (https=)
EP (2) EP3714875A1 (https=)
JP (2) JP6675307B2 (https=)
KR (3) KR20240058976A (https=)
CN (1) CN105764517A (https=)
AU (4) AU2014348369B2 (https=)
CA (1) CA2929689A1 (https=)
CL (1) CL2016001167A1 (https=)
CY (1) CY1123344T1 (https=)
DK (1) DK3068403T3 (https=)
ES (1) ES2819215T5 (https=)
HU (1) HUE050913T2 (https=)
IL (2) IL245548A0 (https=)
MX (2) MX2016006334A (https=)
MY (1) MY176039A (https=)
NZ (1) NZ719953A (https=)
PH (1) PH12016500869A1 (https=)
PL (1) PL3068403T3 (https=)
PT (1) PT3068403T (https=)
RU (1) RU2690841C1 (https=)
SG (1) SG10201809363SA (https=)
SI (1) SI3068403T1 (https=)
UA (1) UA122117C2 (https=)
WO (1) WO2015073895A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116133664A (zh) * 2020-07-16 2023-05-16 视觉治疗股份有限公司 含有糖皮质激素的眼部插入物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3324944A4 (en) * 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389693B (zh) * 2004-04-30 2013-03-21 歐樂根公司 延長治療功效之眼用植入物處理

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CN103402582A (zh) * 2011-02-11 2013-11-20 普西维达公司 使用抗水肿疗法治疗黄斑水肿的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389693B (zh) * 2004-04-30 2013-03-21 歐樂根公司 延長治療功效之眼用植入物處理

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《ARCHIVES OF OPHTHALMOLOGY》 *
《CLINICAL OPHTHALMOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116133664A (zh) * 2020-07-16 2023-05-16 视觉治疗股份有限公司 含有糖皮质激素的眼部插入物

Also Published As

Publication number Publication date
AU2024205640A1 (en) 2024-08-29
US20250319031A1 (en) 2025-10-16
AU2020204362A1 (en) 2020-07-23
NZ719953A (en) 2022-01-28
RU2016119132A (ru) 2017-12-20
ES2819215T3 (es) 2021-04-15
AU2014348369B2 (en) 2020-04-02
MY176039A (en) 2020-07-22
CY1123344T1 (el) 2021-12-31
RU2690841C1 (ru) 2019-06-06
SI3068403T1 (sl) 2020-11-30
MX2016006334A (es) 2016-09-06
ES2819215T5 (en) 2026-04-01
MX2022002306A (es) 2022-03-25
EP3714875A1 (en) 2020-09-30
EP3068403B1 (en) 2020-06-17
EP3068403B2 (en) 2025-12-03
JP2016538292A (ja) 2016-12-08
HUE050913T2 (hu) 2021-01-28
SG10201809363SA (en) 2018-11-29
JP6675307B2 (ja) 2020-04-01
UA122117C2 (uk) 2020-09-25
KR20160085847A (ko) 2016-07-18
PH12016500869B1 (en) 2016-07-04
US20150140062A1 (en) 2015-05-21
DK3068403T3 (da) 2020-09-07
WO2015073895A1 (en) 2015-05-21
KR20220082934A (ko) 2022-06-17
CL2016001167A1 (es) 2017-01-06
CA2929689A1 (en) 2015-05-21
KR102475746B1 (ko) 2022-12-08
JP2020055862A (ja) 2020-04-09
KR20240058976A (ko) 2024-05-07
PH12016500869A1 (en) 2016-07-04
IL290837A (en) 2022-04-01
AU2024205640B2 (en) 2025-10-23
EP3068403A1 (en) 2016-09-21
PL3068403T3 (pl) 2021-01-11
AU2022204607A1 (en) 2022-07-21
PT3068403T (pt) 2020-09-18
JP7022735B2 (ja) 2022-02-18
IL245548A0 (en) 2016-06-30
AU2014348369A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
Gaballa et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives
US20250319031A1 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
JP6132964B2 (ja) 萎縮性加齢性黄斑変性の処置方法
JP5696121B2 (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
JP2014128580A (ja) 硝子体内投与用生分解性インプラント
de Oliveira Dias et al. New drugs and new posterior delivery methods in CME
CN100431544C (zh) 用于治疗病理性眼血管生成的糖皮质激素制剂
HK40038783A (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
Fu et al. Subconjunctival ab externo gel stent implantation for refractory glaucoma after high-risk penetrating keratoplasty
HK1228770A1 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770B (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
Ahuja et al. Post-operative assesment of single subconjunctival triamcinolone acetate injection vs topical corticosteroid in cataract surgery: A prospective control study
Jalkh et al. One Intravitreal Dexamethasone Implant versus Multiple Intravitreal Injections of Triamcinolone Acetonide for Post-Surgical Macular Edema: Efficacy and Safety
Tozer et al. Combined Cataract and Glaucoma Surgery
Yang et al. Long-term Outcomes of Domestic Hunan Aqueous-Drainage Implantation in Refractory Glaucoma
HK1190092B (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160713